Craig B. Reynolds Sells 10,000 Shares of Masimo Co. (NASDAQ:MASI) Stock
Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 11th. The shares were sold at an average price of $279.74, for a total transaction of $2,797,400.00. Following the completion of the sale, the director now directly owns 14,300 shares of the company’s stock, valued at approximately $4,000,282. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of MASI stock opened at $276.27 on Thursday. The stock has a market cap of $15.21 billion, a P/E ratio of 71.76, a P/E/G ratio of 3.90 and a beta of 0.87. The company has a fifty day moving average price of $266.33 and a two-hundred day moving average price of $238.93. Masimo Co. has a one year low of $143.90 and a one year high of $284.86.
Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Saturday, October 31st. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.18. The firm had revenue of $278.11 million during the quarter, compared to analysts’ expectations of $275.00 million. Masimo had a net margin of 20.30% and a return on equity of 15.75%. On average, research analysts expect that Masimo Co. will post 3.46 EPS for the current fiscal year.
MASI has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of Masimo from a “buy” rating to a “hold” rating and set a $258.00 target price for the company. in a research note on Thursday, October 8th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Tuesday, October 6th. BidaskClub raised shares of Masimo from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 6th. Raymond James increased their price objective on shares of Masimo from $250.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 28th. Finally, Stifel Nicolaus increased their price objective on shares of Masimo from $255.00 to $276.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $256.43.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
See Also: Quiet Period Expirations
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.